Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Geron Corporation GERN

Healthcare  —  Biotechnology
1.26 0.00 0.00% as of 25 Sep
Market cap
$815.9M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Geron Corporation (GERN) Business Profile

Updated before January 2025

Company Overview

Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company headquartered in Foster City, California. Founded in 1990, Geron has been at the forefront of developing innovative therapies for the treatment of cancer and other serious diseases. The company is particularly known for its pioneering work in telomerase biology, a field that explores the role of telomerase in cellular aging and cancer. Geron’s leadership team is composed of seasoned professionals with extensive experience in biotechnology and pharmaceutical development. The company’s CEO, Dr. John A. Scarlett, has been instrumental in steering Geron’s strategic direction and advancing its clinical programs.

Core Business Segments

Geron Corporation focuses on the development and commercialization of therapies targeting telomerase, an enzyme that plays a critical role in cancer cell proliferation. The company’s primary product candidate is imetelstat, a first-in-class telomerase inhibitor. Imetelstat is being developed for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and myelofibrosis (MF). These are serious blood disorders with limited treatment options, and imetelstat has shown promising results in clinical trials.

Key Products and Services

  • Imetelstat: Geron’s flagship product candidate, imetelstat, is currently in late-stage clinical trials. It has demonstrated potential in targeting malignant stem and progenitor cells in hematologic cancers.
  • Research and Development: Geron invests heavily in R&D to explore additional applications of telomerase inhibition in oncology and other therapeutic areas.

Business Model

Geron’s business model is centered on the development and commercialization of innovative therapies. The company generates revenue through licensing agreements, collaborations, and potential future product sales. Geron has partnered with leading academic institutions and research organizations to advance its clinical programs. By focusing on a niche area of oncology, Geron aims to address unmet medical needs and create value for patients and stakeholders.

Strategic Direction

Geron’s strategic priorities include:

  1. Advancing Imetelstat: The company is focused on completing Phase 3 clinical trials for imetelstat in MDS and MF. Regulatory submissions and potential market approvals are key milestones.
  2. Expanding Pipeline: Geron is exploring additional indications for telomerase inhibition and investing in preclinical research to identify new therapeutic targets.
  3. Sustainability Goals: While not a primary focus, Geron is committed to ethical practices and minimizing its environmental footprint.
  4. Global Expansion: The company aims to establish a global presence by seeking regulatory approvals in key markets such as the U.S., Europe, and Asia.

Competitive Landscape

Geron operates in a highly competitive biopharmaceutical sector. Key competitors include:

  • Acceleron Pharma: Focused on hematologic and rare diseases.
  • Incyte Corporation: A leader in oncology and hematology therapies.
  • Bristol-Myers Squibb: Offers a broad portfolio of cancer treatments.
  • Gilead Sciences: Known for its expertise in oncology and antiviral therapies.

Despite the competition, Geron’s unique focus on telomerase inhibition sets it apart in the market.

Risk Factors

Geron faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could impact the company’s growth.
  • Market Dependence: The company’s success is heavily reliant on the approval and commercialization of imetelstat.
  • Supply Chain Disruptions: Challenges in manufacturing and distribution could affect product availability.
  • Financial Risks: As a clinical-stage company, Geron depends on external funding and may face financial constraints.

Recent Developments

  • Clinical Trial Progress: Geron recently announced positive interim results from its Phase 3 clinical trial of imetelstat in MDS, bringing it closer to potential regulatory approval.
  • Corporate Strategy: The company has strengthened its leadership team and expanded its R&D capabilities to support future growth.
  • Global Developments: The COVID-19 pandemic posed challenges but also highlighted the importance of innovative therapies in addressing unmet medical needs.

Investment Considerations

Strengths:

  • First-mover advantage in telomerase inhibition.
  • Promising clinical data for imetelstat.
  • Strong leadership and strategic focus.

Risks:

  • Dependence on a single product candidate.
  • High R&D expenses and financial uncertainty.
  • Competitive pressures in the oncology market.

Conclusion

Geron Corporation is a pioneering biopharmaceutical company with a unique focus on telomerase biology. While the company faces challenges, its innovative approach and promising clinical data position it as a potential leader in the treatment of hematologic malignancies. With a clear strategic direction and a commitment to addressing unmet medical needs, Geron is poised for future growth and success in the biopharmaceutical industry.